psychiatry

International Society for Bipolar Disorder: New Guidelines

photo of DSM-IV-TR

Published in the latest(April 2008) issue of Psychiatric Times an article about proposed new diagnostic guidelines for bipolar disorder by the International Society of Bipolar Disorder.

These new proposed guidelines might give insight to what may be set in the DSM-V. The two biggest changes will be discarding the Schizoaffective disorder and addition of a pediatric bipolar disorder.

Zyprexa again

The anti-psychotic Zyprexa is making headlines, again. The amount of money Eli Lilly is paying to defend itself and its tactics in marketing the drug is rising (estimated to be now more than 0.2 billion US dollars since 2004 ). Zyprexa is also one of the most profitable Anti-psychotic medications (almost 5 billion US dollars in 2007).

zyprexa package

Will Zyprexa join Vioxx ?

Blogging on Peer-Reviewed ResearchLilly the manufacturer of the atypical antipsychotic Zyprexa(Olanzapine) and Symbiax(Olanzapine + Fluoxetine) will add a black box warning on its product regarding its metabolic side effects.

Olanzapine is an antipsychotic (AP) used mainly for the treatment of Schizophrenia and Bipolar disorder.

Syndicate content